TRIO and eClinical Solutions to Power Digital Transformation in Cancer Trials
eClinical Solutions LLC has announced that Translational Research in Oncology (TRIO) has selected eClinical’s elluminate clinical data platform for its trial processes across its network of 700+ cancer centers.
The variety of digital health data now collected in clinical research have provided tremendous opportunities for scientific breakthrough. In the last decade, the volume of clinical data has grown by 183%, with over two-thirds of sponsors now using or piloting at least four different data sources in their trials. Despite significant innovation in data collection platforms and capabilities, including those for decentralized clinical trials (DCT), there has been less innovation on the process of ingesting, reviewing, organizing and analyzing these data streams. 75% of companies still rely on existing excel and SAS infrastructure to organize their data once it has been collected.
For more information, click here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
